Meningioma Clinical Trials

62 recruitingLast updated: June 17, 2026

There are 62 actively recruiting meningioma clinical trials across 20 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1, Phase 3. Top locations include Miami, Florida, United States, Columbus, Ohio, United States, San Francisco, California, United States. Updated daily from ClinicalTrials.gov.


Meningioma Trials at a Glance

62 actively recruiting trials for meningioma are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 2 with 22 trials, with the heaviest enrollment activity in Miami, Columbus, and San Francisco. Lead sponsors running meningioma studies include Centre Francois Baclesse, Dartmouth-Hitchcock Medical Center, and Emory University.

Browse meningioma trials by phase

Treatments under study

About Meningioma Clinical Trials

Looking for clinical trials for Meningioma? There are currently 45 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Meningioma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Meningioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 62 trials

Recruiting
Phase 2

177Lu-DOTATATE for Recurrent Meningioma

Recurrent Meningioma
European Organisation for Research and Treatment of Cancer - EORTC136 enrolled19 locationsNCT06326190
Recruiting

Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients

MeningiomaGliomaPrimary Brain Tumor+1 more
Jona Hattangadi-Gluth300 enrolled1 locationNCT05576103
Recruiting
Phase 1Phase 2

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

ParagangliomaPheochromocytomaSolid Tumor Cancer+19 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Phase 2

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
Alliance for Clinical Trials in Oncology124 enrolled780 locationsNCT02523014
Recruiting
Phase 2

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Meningioma
Exelixis100 enrolled3 locationsNCT07428616
Recruiting
Phase 1Phase 2

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Recurrent Meningioma
Joshua Palmer30 enrolled1 locationNCT07150806
Recruiting

Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors

GlioblastomaMeningiomaGlioma+4 more
Medical University of Warsaw200 enrolled1 locationNCT07411690
Recruiting
Not Applicable

Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures

GlioblastomaMeningiomaGlioma+2 more
Medical University of Warsaw382 enrolled1 locationNCT07413796
Recruiting

Cognitive Status After Removal of Skull Base Meningioma

Cognitive ImpairmentCognitive DeclineMeningioma+4 more
Ohio State University50 enrolled1 locationNCT04635657
Recruiting

Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma

Brain TumorMeningiomaMeningioma of Brain
University of California, San Francisco3,000 enrolled1 locationNCT07418775
Recruiting
Not Applicable

Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma

MeningiomaRecurrent MeningiomaMeningioma, Malignant
University of California, San Francisco23 enrolled1 locationNCT06557512
Recruiting
Phase 1Phase 2

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 2

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

Intracranial Meningioma
RTOG Foundation, Inc.153 enrolled12 locationsNCT06955169
Recruiting
Phase 2

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Meningioma
Baptist Health South Florida24 enrolled3 locationsNCT05425004
Recruiting
Phase 2

Regorafenib for Recurrent Meningioma (MIRAGE Trial)

Meningioma, Malignant
Istituto Oncologico Veneto IRCCS104 enrolled17 locationsNCT06275919
Recruiting
Phase 3

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Grade 2 MeningiomaIntracranial Meningioma
NRG Oncology163 enrolled214 locationsNCT03180268
Recruiting
Phase 2

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

Neurofibromatosis type 2MeningiomaEpendymoma+2 more
Scott R. Plotkin, MD, PhD109 enrolled6 locationsNCT04374305
Recruiting
Not Applicable

NK Cell Therapy for Malignant Solid Brain Tumors

Brain MetastasisGlioblastoma Multiforme (GBM)Glioblastoma (GBM)+2 more
Peking University Third Hospital27 enrolled4 locationsNCT07552233
Recruiting
Phase 2

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Grade 2 MeningiomaRecurrent MeningiomaGrade 1 Meningioma+2 more
Mayo Clinic42 enrolled1 locationNCT04082520
Recruiting
Phase 1Phase 2

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

MeningiomaRecurrent Diffuse Intrinsic Pontine GliomaHigh Grade Glioma+10 more
Nationwide Children's Hospital65 enrolled4 locationsNCT05278208